News

Co-Author Craig Mundie and ISB’s Dr. Jim Heath discuss AI’s rapid evolution, ethical considerations, and potential to revolutionize science and society in a compelling Town Hall event.

ISB researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.

Scientists at the Institute for Systems Biology (ISB) reveal how T cells “decide” their fate in fighting infections like COVID-19, paving the way for improved treatments for infections, cancer, and autoimmune diseases.

Infection, autoimmunity and cancer account for 40 percent of deaths worldwide. In a Cell Reports paper, ISB researchers detail how the human immune system works in common ways across diseases – findings that offer promising avenues for exploring multi-disease therapeutic strategies.

In a breakthrough discovery that changes how we understand T cells and with implications of how we can better engineer custom immune responses to fight disease, Institute for Systems Biology researchers showed that the different disease-fighting functions of different T cells are determined by the genetically encoded T-cell receptor sequence that are unique to those cells.

In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.